Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region. Renata has nearly two decades of experience in senior leadership roles and joins from Fortrea, where she led Clinical Operations Delivery and Clinical Projects. LATAM represents 10% of the world's clinical research sites and is a critical focus for Velocity's expansion strategy, which has already delivered accelerated growth in Europe. In just 24 months, Velocity has successfully scaled to 17 European sites across three countries; it now employs a team of 150 in the region, accounting for 10% of Velocity's workforce. Renata's appointment signals Velocity's ambition to further extend its global network. As LATAM MD, she will spearhead the identification, acquisition, and operations of new regional sites. Paul Evans, V
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential' will drive long-term growth [Fortune]Fortune
- BerGenBio Appoints Olav Hellebø as CEO [Yahoo! Finance]Yahoo! Finance
- Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies [Yahoo! Finance]Yahoo! Finance
- NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NYSE: NVS) had its "hold" rating re-affirmed by analysts at Erste Group Bank AG.MarketBeat
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website